<?xml version='1.0' encoding='utf-8'?>
<document id="2427003"><sentence text="Disopyramide: clinical indications, pharmacokinetics and laboratory assessment."><entity charOffset="0-12" id="DDI-PubMed.2427003.s1.e0" text="Disopyramide" /></sentence><sentence text="Disopyramide is an antiarrhythmic drug similar to quinidine and used primarily to treat ventricular ectopic systoles"><entity charOffset="0-12" id="DDI-PubMed.2427003.s2.e0" text="Disopyramide" /><entity charOffset="50-59" id="DDI-PubMed.2427003.s2.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.2427003.s2.e0" e2="DDI-PubMed.2427003.s2.e0" /><pair ddi="false" e1="DDI-PubMed.2427003.s2.e0" e2="DDI-PubMed.2427003.s2.e1" /></sentence><sentence text=" Unlike quinidine which shows drug-drug interaction with digoxin, disopyramide appears to be free of this problem"><entity charOffset="8-17" id="DDI-PubMed.2427003.s3.e0" text="quinidine" /><entity charOffset="57-64" id="DDI-PubMed.2427003.s3.e1" text="digoxin" /><entity charOffset="66-78" id="DDI-PubMed.2427003.s3.e2" text="disopyramide" /><pair ddi="false" e1="DDI-PubMed.2427003.s3.e0" e2="DDI-PubMed.2427003.s3.e0" /><pair ddi="false" e1="DDI-PubMed.2427003.s3.e0" e2="DDI-PubMed.2427003.s3.e1" /><pair ddi="false" e1="DDI-PubMed.2427003.s3.e0" e2="DDI-PubMed.2427003.s3.e2" /><pair ddi="false" e1="DDI-PubMed.2427003.s3.e1" e2="DDI-PubMed.2427003.s3.e1" /><pair ddi="false" e1="DDI-PubMed.2427003.s3.e1" e2="DDI-PubMed.2427003.s3.e2" /></sentence><sentence text=" Side effects include anticholinergic symptoms, cardiovascular problems, and some gastrointestinal discomfort" /><sentence text=" Disopyramide is metabolized to N-desisopropyl disopyramide in the liver with approximately 50 percent of the parent drug excreted unchanged"><entity charOffset="1-13" id="DDI-PubMed.2427003.s5.e0" text="Disopyramide" /><entity charOffset="32-59" id="DDI-PubMed.2427003.s5.e1" text="N-desisopropyl disopyramide" /><pair ddi="false" e1="DDI-PubMed.2427003.s5.e0" e2="DDI-PubMed.2427003.s5.e0" /><pair ddi="false" e1="DDI-PubMed.2427003.s5.e0" e2="DDI-PubMed.2427003.s5.e1" /></sentence><sentence text=" The elimination half-life varies from 4" /><sentence text="5 to nine hours, and it can be even longer in cases of renal failure or myocardial infarction" /><sentence text=" There exists an extremely variable degree of protein binding (10 to 70 percent), which is highly dependent on concentration" /><sentence text=" The unbound (free) fraction increases with increasing drug concentration, making the interpretation of total disopyramide concentrations very difficult"><entity charOffset="110-122" id="DDI-PubMed.2427003.s9.e0" text="disopyramide" /></sentence><sentence text=" Since the free drug concentration is more representative of availability to its receptor, and only the free fraction is available for renal excretion, the free drug concentration may represent a better predictor of therapeutic effectiveness" /><sentence text=" Methods for determining concentrations of disopyramide include gas chromatography, high performance liquid chromatography, homogeneous enzyme immunoassay (EMIT), and fluorescence polarization immunoassay"><entity charOffset="43-55" id="DDI-PubMed.2427003.s11.e0" text="disopyramide" /></sentence><sentence text=" A method for performing both total and free disopyramide determinations is also described"><entity charOffset="45-57" id="DDI-PubMed.2427003.s12.e0" text="disopyramide" /></sentence><sentence text="" /></document>